Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has the Viral Hepatitis Market Size Changed, over the years?

Continuous growth has been observed in the viral hepatitis market size over previous years. The market is projected to expand from $16.21 billion in 2024 to $16.93 billion in 2025, boasting a compound annual growth rate (CAGR) of 4.4%. Factors such as the advancement in vaccine development, increased frequency of blood screening programs, the use of antiviral drugs, and global health initiatives have been key contributors to this growth in the historic period.

How Much Will the Viral Hepatitis Market Be Worth in 2029?

In the coming years, the market size of viral hepatitis is predicted to experience consistent growth, eventually reaching $19.97 billion in 2029 with a compound annual growth rate (CAGR) of 4.2%. The growth anticipated in this forecasted period can be associated with factors like access to treatment options, public health regulations, combined therapies, and health equality initiatives. Significant trends projected during this same period range from individualized treatment plans and digital health gadgets, to AI’s role in disease monitoring and the micro-elimination of hepatitis C.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13028&type=smp

Which is the Largest Company in the Viral Hepatitis Market?

Major companies operating in the viral hepatitis market are Pfizer Inc., Johnson & Johnson Co, F Hoffmann-La Roche AG, Merck & Co., AbbVie Inc., Novartis AG, Sanofi SA, Bristol-Myers Squibb, Astra Zeneca Pharmaceuticals LP, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Gilead Sciences Inc., Viatris Inc., Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Daiichi Sankyo Co. Ltd., Hetero Drugs Ltd., Eisai Co. Ltd., Boehringer Ingelheim Group, Sun Pharmaceutical Industries Ltd., Lupin Limited, Dr. Reddy’s Laboratories, Zydus Lifescience Ltd., Glenmark Pharmaceuticals Ltd., Cipla Ltd., Torrent Pharmaceuticals Ltd., Otsuka Pharmaceutical Co. Ltd., Wockhardt Ltd.

What Are the Main Market Drivers in the Viral Hepatitis Industry?

The escalating incidences of hepatitis are anticipated to spur the expansion of the viral hepatitis market in the future. Hepatitis, a liver infection, is triggered by multiple infectious viruses and non-infectious agents that can lead to various health complications. Hepatitis A, B, C, D, and E are the viruses that can induce viral hepatitis, leading to inflammation and damage in the liver. For example, in April 2024, the European Centre for Disease Prevention and Control, a health agency based in Sweden, reported 28,855 hepatitis B virus (HBV) infections across 30 EU/EEA Member States in 2022, a 78% rise from 16,187 cases in the previous year. Furthermore, the case count in 2022, standing at 28,420, equates to a crude rate of 8.5 cases per 100,000 individuals. Hence, the swelling prevalence of hepatitis will catalyze the growth of the viral hepatitis market. Expanding research and developmental pursuits will fuel the growth of the viral hepatitis market. The domain of research and development (R&D) for viral hepatitis includes an array of activities like vaccine development, antiviral medications, diagnostic tests, epidemiology studies, public health interventions, genomic exploration, prevention strategies, global health campaigns, clinical trials, and probing into co-infections. Increased flow into these activities will result in innovative treatment methodologies, broader diagnostic and prevention options, increased clinical trials, amplified global health initiatives, and intensified competition among pharmaceutical firms. For instance, in November 2022, The Peter Doherty Institute for Infection and Immunity, a research institution based in Australia, revealed that Melbourne researchers secured funding of $1.7 million for the next five years from the mRNA Victoria Activation Program for advancing their groundbreaking work to discover a cure for hepatitis B virus infection. Hence, the surge in research and development activities will contribute to the burgeoning growth of the viral hepatitis market in the upcoming years.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=13028&type=smp

How Is the Viral Hepatitis Market Segments Structured?

The viral hepatitis market covered in this report is segmented –

1) By Disease Type: Hepatitis A, Hepatitis B, Hepatitis C, Other Disease Types

2) By Diagnosis: Liver Biopsy, Blood Tests, Imaging Tests, Other Diagnosis

3) By Treatment: Antiviral Drugs, Surgery, Vaccine, Immune Modulator Drugs, Other Treatments

4) By Route Of Administration: Oral, Parenteral, Other Routes Of Administration

5) By End-Users: Hospitals, Specialty Clinics, Homecare, Other End-Users

Subsegments:

1) By Hepatitis A: Acute Hepatitis A, Chronic Hepatitis A

2) By Hepatitis B: Acute Hepatitis B, Chronic Hepatitis B, Hepatitis B Carrier

3) By Hepatitis C: Acute Hepatitis C, Chronic Hepatitis C

4) By Other Disease Types: Hepatitis D, Hepatitis E

What Strategic Trends Are Transforming the Viral Hepatitis Market?

Firms within the viral hepatitis market are focusing on the progression and innovation of new drugs to maintain their market standing. The advancement in drug development not only enhances scientific comprehension by providing a deeper understanding of disease mechanisms, but also speeds up the creation of novel treatments. For example, Gilead Sciences Inc., an American biopharmaceutical firm, declared in November 2022 that the FDA had given a supplemental new drug application (sNDA) for Vemlidy (tenofovir alafenamide) 25 mg tablets. This drug is intended to be a daily treatment for chronic hepatitis B virus (HBV) infection in children aged 12 and over who have compensated liver disease. The approval of Vemlidy for this particular patient group was backed by the results of a 24-week Phase 2 clinical trial.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/viral-hepatitis-global-market-report

Which Global Regions Offer the Highest Growth in the Viral Hepatitis Market?

North America was the largest region in the viral hepatitis market in 2024. The regions covered in viral hepatitis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13028

This Report Delivers Insight On:

1. How big is the viral hepatitis market, and how is it changing globally?

2. Who are the major companies in the viral hepatitis market, and how are they performing?

3. What are the key opportunities and risks in the viral hepatitis market right now?

4. Which products or customer segments are growing the most in the viral hepatitis market?

5. What factors are helping or slowing down the growth of the viral hepatitis market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model